Sozinibercept

Opthia may owe up to $1 billion to investors following the failure of sozinibercept in clinical trials for wet age-related macular degeneration (WetAMD).

The European Medicines Agency has validated the application to extend Aspaveli® (pegcetacoplan) use for treating C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, two rare kidney diseases currently lacking approved treatments.

Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.

The FDA has approved Roche's Susvimo (ranibizumab injection) for treating diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes.

Canaccord Genuity initiates coverage on Opthea with a buy rating, citing strong potential for their lead drug OPT-302 in treating wet AMD and DME. The drug's unique mechanism targeting VEGF-C and VEGF-D pathways, combined with promising Phase II results showing significant vision improvements, positions it as a potential breakthrough treatment for patients who don't respond well to current therapies.